Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMXT 1501 + IV DFMO in Advanced Cancer
NCT05500508Phase 2Terminated
- Sponsor
- Aminex Therapeutics
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of AMXT-1501 in solid tumor (advanced stage), diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), sponsored by Aminex Therapeutics. Started Nov 2022; status: terminated.
02
Drugs
AMXT-1501
03
Conditions
solid tumor (advanced stage)diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT05500508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05500508.